Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer

BJU International

Volumn 110, Issue SUPPL. 1, 2012, Pages 14-22

  Clarke, Noel W ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

castration resistant prostate cancer; chemotherapy; immunotherapy; prostate cancer; survival; treatment

Indexed keywords

ATRASENTAN; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CA 184 043; CABAZITAXEL; CABOZANTINIB; CALCITRIOL; CARBOPLATIN; DENOSUMAB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; MITOXANTRONE; PLACEBO; PREDNISONE; RADIUM CHLORIDE RA 223; RHENIUM; RILIMOGENE GALVACIREPVEC; SAMARIUM 153; SIPULEUCEL T; STRONTIUM 89; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; ZIBOTENTAN; ZOLEDRONIC ACID;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BONE METASTASIS; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL THERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; HUMAN; METASTASIS; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATECTOMY; QUALITY OF LIFE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; WATCHFUL WAITING;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ENDOTHELIN; RESEARCH; TAXOIDS; TREATMENT OUTCOME;

EID: 84867563211     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11430.x     Document Type: Article

References (74)

1. Heidenreich A, Bolla M, Joniau S, et al,. EAU Guidelines on Prostate cancer 2011. Available at: http://www.uroweb.org/gls/pdf/08-Prostate- Cancer%20September%2022nd%202011.pdf. Accessed July 2012
2. Tannock IF, Osoba D, Stockler MR, et al,. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996; 14: 1756-64 (Pubitemid 26185452)
3. Tannock IF, de Wit R, Berry WR, et al,. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 (Pubitemid 39315317)
4. Petrylak DP, Tangen CM, Hussain MH, et al,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20 (Pubitemid 39315318)
5. de Bono JS, Oudard S, Ozguroglu M, et al,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
6. Yagoda A, Petrylak D,. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71 (Suppl.): 1098-109 (Pubitemid 23049638)
7. Dahut W, Gulley J, Arlen P, et al,. Randomized phase II trial of docetaxel plus thalidomide in androgen independent prostate cancer. J Clin Oncol 2004; 22: 2532-9 (Pubitemid 41103740)
8. Ning Y, Gulley J, Arlen P, et al,. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 2070-6
9. Scher HI, Jia X, Chi K, et al,. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011; 29: 2191-8
10. Oh W, Halabi S, Kelly W, et al,. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone refractory prostate carcinoma: cancer and Leukemia Group B 99813. Cancer 2003; 98: 2592-8 (Pubitemid 37509522)
11. Picus J, Halabi S, Kelly WK, et al,. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 2011; 117: 526-33
12. Berthold DR, Pond GR, Soban F, et al,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5
13. Berthold DR, Pond GR, Roessner M, et al,. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008; 14: 2763-7
14. Ansari J, Choo B, Hussain A, et al,. Docetaxel retreatment as second- and third-line chemotherapy in metastatic hormone refractory prostate cancer patients pretreated with docetaxel: An updated analysis. 2009 GU ASCO meeting, abstract 185.
15. Horwich A, Parker C, Bangma C, et al,. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals Oncol 2010; 21 (Suppl. 5): v129-33
16. Yasufuku T, Shigemura K, Matsumoto O, Arakawa S, Fujisawa M,. Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer. J Infect Chemother 2010; 16: 200-5
17. Petrioli R, Pascucci A, Conca R, et al,. Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. Br J Cancer 2011; 104: 613-9
18. Beer TM, Hough KM, Garzotto M, et al,. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 2001; 28 (Suppl. 15): 49-55 (Pubitemid 32947552)
19. Small EJ, Schellhammer PF, Higano CS, et al,. Placebo controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-94 (Pubitemid 46638945)
20. Kantoff PW, Higano CS, Shore ND, et al,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22
21. Higano C, Schellhammer P, Small E, et al,. Integrated data from 2 controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-9
22. Higano C, Corman J, Smith D, et al,. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008; 113: 975-84
23. Small E, Sacks N, Nemunaitis J, et al,. Granulocyte macrophage colony stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 3883-91 (Pubitemid 47037595)
24. Small E, Demkow T, Gerritsen WR, et al,. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. Genitourinary Cancer Symposium 2009. Available at: http://www.asco.org/ascov2/ Meetings/Abstracts?&vmview=abst-detail-view&confID=64&abstractID= 20295. Accessed July 2012
25. Higano C, Saad F, Somer B, et al,. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. Genitourinary Cancer Symposium 2009. Available at: http://www.asco.org/ascov2/Meetings/Abstracts? &vmview=abst-detail-view&confID=64&abstractID=20543. Accessed July 2012
26. Hodi FS, O'Day SJ, McDermott DF, et al,. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23
27. Fong L, Kwek SS, O'Brien S, et al,. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69: 609-15
28. Beer TM, Slovin SF, Higano CS, et al,. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2008; 26 (Suppl.): abstract 5004
29. Hodge JW, Greiner JW, Tsang KY, et al,. Co-stimulatory molecules as adjuvants for immunotherapy. Front Biosci 2006; 11: 788-803
30. Kantoff PW, Schuetz TJ, Blumenstein BA, et al,. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-105
31. Coleman RE,. Skeletal complications of malignancy. Cancer 1997; 8 (Suppl.): 1588-94 (Pubitemid 27444031)
32. Clarke NW, Fleisch H,. Biology of bone metastases and the role of bisphosphonates. In:, Ablin RJ, Mason M, eds, Cancer Metastasis: Biology and Treatment. The Netherlands: Springer, 2007, pp. 253-82
33. Saad F, Gleason DM, Murray R, et al,. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-82 (Pubitemid 38807610)
34. Clarke NW,. Bisphosphonates: do we have a toxicity problem? Eur Urol 2008; 54: 974-5
35. Body JJ, Facon T, Coleman RE, et al,. A study of the biological receptor activator of nuclear factor kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-8 (Pubitemid 43342512)
36. Fizazi K, Lipton A, Mariette X, et al,. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-71
37. Fizazi K, Carducci M, Smith M, et al,. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-22
38. Smith MR, Saad F, Coleman R, et al,. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46
39. Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 1999; 52: 111-21
40. van der Linden YM, Lok JJ, Steenland E, et al,. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys 2004; 59: 528-37 (Pubitemid 38622611)
41. Papatheofanis FJ, Smith C, Najib M,. Improvement in sensory pain rating after palliative systemic radionuclide therapy in patients with advanced prostate cancer. Am J Ther 2009; 16: 127-32
42. Baczyk M, Milecki P, Baczyk E, Sowiński J,. The effectiveness of strontium 89 in palliative therapy of painful prostate cancer bone metastases. Ortop Traumatol Rehabil 2003; 5: 364-8 (Pubitemid 38647978)
43. Porter AT, McEwan AJ,. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol 1993; 20 (Suppl. 2): 38-43 (Pubitemid 23170172)
44. Quilty PM, Kirk D, Bolger JJ, et al,. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40 (Pubitemid 24167588)
45. Oosterhof GO, Roberts JT, de Reijke TM, et al,. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003; 44: 519-26 (Pubitemid 37328625)
46. Serafini AN, Houston SJ, Resche I, et al,. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 1574-81 (Pubitemid 28175783)
47. Sartor O, Reid RH, Hoskin PJ, et al,. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63: 940-5 (Pubitemid 38596683)
48. Nilsson S, Franzén L, Parker C, et al,. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587-94 (Pubitemid 46995621)
49. TM) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer 2011; 47 (Suppl. 2): 3
50. Tu S-M, Millikan RE, Mengistu B, et al,. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357: 336-41 (Pubitemid 32128538)
51. ClinicalTrials.gov. Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00554918?term=trapeze+trial&rank=2. Accessed July 2012
52. Nelson J, Bagnato A, Battistini B, Nisen P,. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3: 110-6 (Pubitemid 37328878)
53. Okazawa M, Shiraki T, Ninomiya H, Kobayashi S, Masaki T,. Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 1998; 273: 12584-92 (Pubitemid 28240635)
54. Nelson JB, Love W, Chin JL, et al,. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113: 2478-87
55. Carducci MA, Saad F, Abrahamsson PA, et al,. A phase 3 randomized controlled trial of the eYcacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 1959-66 (Pubitemid 350036854)
56. James ND, Caty A, Borre M, et al,. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 1112-23
57. ClinicalTrials.gov. A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer (ENTHUSE M0). Available at: http://clinicaltrials.gov/ct2/show/NCT00626548. Accessed July 2012
58. George D, Halabi S, Shepard T, et al,. Prognostic signifi cance of plasma vascular endothelial growth factor levels in patients with hormone refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-6 (Pubitemid 32994827)
59. Sonpavde G, Periman PO, Bernold D, et al,. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21: 319-24
60. Ogita S, Tejwani S, Heilburn LK, et al,. Phase II trial of bevacizumab monotherapy in nonmetastatic castrate-resistant prostate cancer (CRPC). J Clin Oncol 2011; 29 (Suppl. 7): abstract 33
61. Kelly WK, Halabi S, Carducci MA, et al,. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012; 30: 1534-40
62. Cooper CS,. The met oncogene: from detection by transfection to transmembrane receptor for hepatocyte growth factor. Oncogene 1992; 7: 3-7
63. Hussain M, Smith MR, Sweeney C, et al,. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol 2011; 29 (Suppl.): abstract 4516
64. Yu E, Wilding G, Posadas E, et al,. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7421-8
65. Araujo J, Armstrong AJ, Braud EL, et al,. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086). J Clin Oncol 2009; 27 (Suppl.): abstract 5061
66. Miyake H, Nelson C, Rennie PS, et al,. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000; 60: 170-6 (Pubitemid 30058748)
67. Zellweger T, Chi K, Miyake H, et al,. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002; 8: 3276-84 (Pubitemid 35155041)
68. Miyake H, Chi KN, Gleave ME,. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000; 6: 1655-63 (Pubitemid 30305057)
69. Chi KN, Hotte SJ, Yu EY, et al,. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 4247-54
70. Sreedhar AS, Csermely P,. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther 2004; 101: 227-57 (Pubitemid 38340861)
71. Garrido C, Ottavi P, Fromentin A, et al,. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 1997; 57: 2661-7 (Pubitemid 27283777)
72. Rocchi P, So A, Kojima S, et al,. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004; 64: 6595-602 (Pubitemid 39297919)
73. Rocchi P, Jugpal P, So A, Sinneman S, et al,. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int 2006; 98: 1082-9 (Pubitemid 44536463)
74. Chi KN, Hotte SJ, Ellard S, et al,. A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. J Clin Oncol 2012; 30 (Suppl. 5): abstract 121